Background:  Ataxia-telangiectasia (AT) is an autosomal recessive human genetic disease characterized by an elevated risk of cancer, immune defects, genetic instability and an increased sensitivity to radiation. For example, 10-15% of AT patients suffer an extremely high incidence of lymphoid malignancies incuding both T and B cell tumors by early adulthood. Interestingly, there is a total absence of myloid tumors in these patients. Although AT homozygotes are rare, the AT gene is likely to play a role in sporadic breast cancer and other common cancers. The human AT gene has been mapped to chromosome 11q22-q23. The AT group D complementing gene has been cloned. The protein, designated ATDC, has been shown to interact with the intermediate filament protein vimentin, a substrate for the PKC family of protein kinases, and with hPKCI-1, an inhibitor of the PKCs. Examination of the predicted ATDC amino acid sequence has revealed the presence of both zinc finger and leucine zipper motifs, suggesting that the protein may form homodimers and possibly associate with DNA.

Description: Rabbit polyclonal to TRIM29

Immunogen: KLH conjugated synthetic peptide derived from TRIM29

Specificity:  ·Reacts with Human, Mouse, Pig, Dog and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 66 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.